Expert Interview
Discussing Emerging Neurostimulation Therapies for moderate-to-severe Obstructive Sleep Apnea, including LivaNova’s Aura6000 System
Ticker(s): LIVN, NSPR, LLY, NVOInstitution: Johns Hopkins
- Medical Director, Johns Hopkins Sleep Disorders Center and Associate Professor of Neurology at JHU School of Medicine.
- Actively treats over 1,500 patients with OSA, 20-30 patients with Narcolepsy, and 40-50 patients with Idiopathic Hypersomnia.
- Research interests are in the area of sleep medicine, specifically investigating the co-morbid health consequences of chronic sleep deprivation.
What do you see as the biggest challenges or barriers to widespread use of this type of therapy?
Added By: dami_adminHow does Aura6000 compare to existing treatment options like CPAP or other implantable devices?
Added By: dami_adminHow are patients with moderate-to-severe sleep apnea typically treated today, and where are the biggest gaps in care?
Added By: dami_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
